Company family · HQ JP
Mochida: medicine shortages
4534 · Tokyo
As of 2 Nov 2026, 7 Mochida products have a reported shortage across 1 countries, covering 3 medicines.
Products short7rank #253 of 464
Medicines3active ingredients
Countries1/16
New in 90 days20 vs market pace
Typical duration2.5 yearsmedian so far
Manufacturing0%demand-driven 71%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Pegfilgrastim | 2 | 8 Apr 2024 | Increased demand | 2/16 | |
| Tocilizumab | 2 | 6 Oct 2026 | Increased demand | 5/16 | |
| Urokinase | 2 | 1 Mar 2024 | Active ingredient shortage | 3/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.